Botulinumtoxin A in der Kopfschmerztherapie

Gaul, Charly; Holle-Lee, Dagny; Straube, Andreas

doi:10.1007/s00115-016-0138-5

Cited by 7 publications

(5 citation statements)

References 49 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first evidence for an effect of BoNT on migraine was the serendipitous observation of an improvement of migraine in patients treated with BoNT for hyperfunctional lines of the face made in the late 1990s by a plastic surgeon [70]. In the subsequent years, several exploratory studies with BoNT-A using heterogeneous doses and injection paradigms were carried out in migraine and tension-type headache and chronic daily headache with inconclusive and mostly negative results [62,63,[71][72][73][74]. A subgroup analysis of 228 CDH patients enrolled in the randomized placebo-controlled study by Mathew et al showed that the patients without prophylactic medication at the date of study enrolment experienced a significant reduction in the number of headaches in a 30-day period.…”

Section: Onabotulinumtoxin Amentioning

confidence: 99%

Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action

Sprenger¹,

Viana²,

Tassorelli

2018

Neurotherapeutics

View full text Add to dashboard Cite

A relatively high number of different medications is currently used for migraine prevention in clinical practice. Although these compounds were initially developed for other indications and differ in their mechanisms of action, some general themes can be identified from the mechanisms at play. Efficacious preventive drugs seem to either suppress excitatory nervous signaling via sodium and/or calcium receptors, facilitate GABAergic inhibition, reduce neuronal sensitization, block cortical spreading depression and/or reduce circulating levels of CGRP. We here review such mechanisms for the different compounds.

show abstract

Section: Onabotulinumtoxin Amentioning

confidence: 99%

Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action

Sprenger¹,

Viana²,

Tassorelli

2018

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…The inhibition of acetylcholine release by BTX results in the suppression of nerve excitation transmission. Beyond its paralytic effects, recent studies propose an analgesic impact achieved by blocking the release of algogenic neuropeptides, including substance P, neurokinin A, and calcitonin gene-related peptide, as well as glutamate, in primary small-diameter type C afferent nerve fibers [ 79 , 82 ]. The recommended dosage for injection near the nerve trunk [ 81 ] appears to be in the range of 50–200 IU, despite the lack of current approval for this indication.…”

Section: Treatment Of Traumatic Nerve Injurymentioning

confidence: 99%

Clinical insights into traumatic injury of the inferior alveolar and lingual nerves: a comprehensive approach from diagnosis to therapeutic interventions

Kämmerer,

Heimes,

Hartmann

et al. 2024

Clin Oral Invest

View full text Add to dashboard Cite

Objectives This scoping review explores the risk and management of traumatic injuries to the inferior alveolar and lingual nerves during mandibular dental procedures. Emphasizing the significance of diagnostic tools, the review amalgamates existing knowledge to offer a comprehensive overview. Materials and methods A literature search across PubMed, Embase, and Cochrane Library informed the analysis. Results Traumatic injuries often lead to hypo-/anesthesia and neuropathic pain, impacting individuals psychologically and socially. Diagnosis involves thorough anamnesis, clinical-neurological evaluations, and radiographic imaging. Severity varies, allowing for conservative or surgical interventions. Immediate action is recommended for reversible causes, while surgical therapies like decompression, readaptation, or reconstruction yield favorable outcomes. Conservative management, utilizing topical anesthesia, capsaicin, and systemic medications (tricyclic antidepressants, antipsychotics, and serotonin-norepinephrine-reuptake-inhibitors), proves effective for neuropathic pain. Conclusions Traumatic nerve injuries, though common in dental surgery, often go unrecorded. Despite lacking a definitive diagnostic gold standard, a meticulous examination of the injury and subsequent impairments is crucial. Clinical relevance Tailoring treatment to each case's characteristics is essential, recognizing the absence of a universal solution. This approach aims to optimize outcomes, restore functionality, and improve the quality of life for affected individuals. Graphical abstract

show abstract

“…In addition, onabotulinumtoxinA has been shown to be effective in the treatment of chronic migraine in numerous studies [37,38] . Several other studies in subsequent years have failed to show beneficial effects on chronic migraine, and the results of controlled clinical trials have been inconsistent [39,40] .…”

Section: 5%mentioning

confidence: 99%

Results of Treating patients with Chronic Migraine with OnabotulinumtoxinA alone Versus Its Combination with Other Prophylactic Drugs

Abdelrohman

Osman

2022

International Journal of Medical Arts

View full text Add to dashboard Cite

Article informationBackground: Chronic migraine [CM] is a severe neurological disorder characterized by pulsating unilateral or bilateral headache episodes. In people with chronic migraine, onabotulinumtoxinA could reduce the frequency and severity of migraines. Patients report that the treatment is well tolerated. The Aim of The Work:The aim of this study was to evaluate the efficacy of onabotulinumtoxinA injection compared with the efficacy of onabotulinumtoxinA injection in combination with other oral prophylactics. Materials and Methods:This observational study included one hundred five patients with chronic migraine attending the neurology clinic at Almoosa Specialized Hospital in Saudi Arabia, and was conducted from November 2019 to January 2021. Forty-five patients [42.9%] received an injection of onabotulinumtoxinA alone [group A], and 60 patients [57.1%] received a combined injection of onabotulinum-toxinA plus oral prophylaxis [group B]. Results:The study included 105 patients. The mean age of participants was 41.2 ± 5.7 years and ranged from 35 to 55 years. Seventy women [66.7%] and 35 men [33.3%] were affected. The mean frequency of migraine days showed a significant reduction from 17.6±10.3 days per month to 7.2±4.3 days after treatment in patients receiving onabotulinum toxin-A in combination with oral prophylactic medication, whereas it showed a less significant reduction from 16.4 ± 10.4 days per month to 9.1 ± 2.4 days in patients receiving onabotulinum toxin-A alone. Mean treatment frequency per month and mean duration of migraine attacks per hour were also significantly reduced after treatment in both groups. Conclusion:Onabotulinum toxin-A toxin injection is highly effective in treating patients with chronic daily migraine, reducing the number and severity of migraine attacks per month and improving the quality of life of migraine patients. However, it is even more effective when combined with other prophylactic medications depending on the patients' concomitant diseases.

show abstract

Botulinumtoxin A in der Kopfschmerztherapie

Cited by 7 publications

References 49 publications

Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action

Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action

Clinical insights into traumatic injury of the inferior alveolar and lingual nerves: a comprehensive approach from diagnosis to therapeutic interventions

Results of Treating patients with Chronic Migraine with OnabotulinumtoxinA alone Versus Its Combination with Other Prophylactic Drugs

Contact Info

Product

Resources

About